Template:Diethylcarbamazine: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Diethylcarbamazine|{{fontcolor|#6C7B8B|Diethylcarbamazine}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Diethylcarbamazine|{{fontcolor|#6C7B8B|Diethylcarbamazine}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | HETRAZAN<sup>®</sup> WHO Prescribing Information | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Diethylcarbamazine description|Description]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Diethylcarbamazine description|Description]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Diethylcarbamazine indications and usage|Indications and Usage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Diethylcarbamazine indications and usage|Indications and Usage]] | ||
| Line 17: | Line 13: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Diethylcarbamazine adverse reactions|Adverse Reactions]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Diethylcarbamazine adverse reactions|Adverse Reactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Diethylcarbamazine overdosage|Overdosage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Diethylcarbamazine overdosage|Overdosage]] | ||
| Line 25: | Line 19: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Diethylcarbamazine how supplied|How Supplied]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Diethylcarbamazine how supplied|How Supplied]] | ||
|- | |- | ||
|} | |} | ||
Latest revision as of 02:17, 7 January 2014
| Diethylcarbamazine |
|---|
| HETRAZAN® WHO Prescribing Information |
| Description |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| How Supplied |